Current Molecular-Targeted Therapies in NSCLC and Their Mechanism of Resistance
Lung cancer is treated with many conventional therapies, such as surgery, radiation, and chemotherapy. However, these therapies have multiple undesirable side effects. To bypass the side effects elicited by these conventional treatments, molecularly-targeted therapies are currently in use or under d...
Main Authors: | Zachary Schrank, Gagan Chhabra, Leo Lin, Tsatsral Iderzorig, Chike Osude, Nabiha Khan, Adijan Kuckovic, Sanjana Singh, Rachel J. Miller, Neelu Puri |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6694/10/7/224 |
Similar Items
-
Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer
by: Chike Osude, et al.
Published: (2022-05-01) -
New Generations of Tyrosine Kinase Inhibitors in Treating NSCLC with Oncogene Addiction: Strengths and Limitations
by: Ilaria Attili, et al.
Published: (2023-10-01) -
Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies
by: Alberto D’Angelo, et al.
Published: (2020-11-01) -
Treating Cancer by Targeting Telomeres and Telomerase
by: Marko Ivancich, et al.
Published: (2017-02-01) -
Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance
by: Wen-Shuo Wu, et al.
Published: (2014-06-01)